Gatipotuzumab

Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1) . Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) [1][2].

Product Specifications

CAS Number

[1264737-26-9]

Product Name Alternative

PankoMab; DS-3939a antibody

UNSPSC

12352203

Target

Mucin

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gatipotuzumab.html

Purity

96.14

Solubility

H2O

Smiles

[Gatipotuzumab]

Molecular Weight

(146.56 kDa)

References & Citations

[1]Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. European Journal of Cancer, 2020, 138: S5-S6.|[2]Danielczyk A, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006 Nov;55 (11) :1337-47.